depending on the scope and regulatory body:

• Single Patient IND: For individual cases, including emergencies (U.S. FDA)
• Intermediate-size Patient Population: For groups not eligible for a clinical trial
• Treatment IND: For broader access during the drug’s late-stage development
• Named Patient Program (EU): Physicians request unapproved drugs for specific patients
• Group Program: Coordinated use for defined patient categories (e.g., compassionate use for a genetic subtype)

Eligibility Criteria for Compassionate Use

Although terminology and scope vary, the typical eligibility requirements are:

• Patient has a serious or life-threatening condition
• No comparable or satisfactory alternative therapies
• Patient is not eligible for ongoing clinical trials
• Potential benefits outweigh the anticipated risks
• Access will not interfere with the drug’s development program

In all cases, regulatory agencies require submission of safety data, physician certifications, and IRB/ethics committee approvals before treatment begins.

Continue Reading: Application Process, Ethical Considerations, and Global Case Studies

Application Process for Compassionate Use Programs

The process for obtaining access to an investigational product under compassionate use involves multiple steps, which vary by jurisdiction but generally follow a consistent structure:

1. Physician Request: The treating physician initiates the request and confirms that the patient meets eligibility criteria.
2. Sponsor Consent: The drug sponsor must agree to provide the investigational product and often assists with regulatory documentation.
3. Ethics Committee/IRB Approval: Mandatory for protecting patient rights and ensuring ethical justification.
4. Regulatory Submission: A formal application is submitted to the competent authority (e.g., FDA, EMA, Health Canada).
5. Treatment Authorization: Once approved, treatment can begin under strict monitoring and reporting requirements.

In the U.S., the ClinicalTrials.gov platform also allows sponsors to register their expanded access programs to improve transparency.

Ethical and Legal Considerations

Providing investigational drugs outside clinical trials raises several ethical and regulatory questions. Common concerns include:

• Informed Consent: Patients must fully understand that the product is not yet approved, and its safety/efficacy is unproven.
• Equity and Fairness: Access should be based on medical need, not personal connections or geography.
• Impact on Clinical Trials: Widespread use of compassionate use could reduce enrollment in pivotal studies.
• Data Collection: Sponsors must ensure any data collected under compassionate use aligns with GCP and regulatory expectations.

To mitigate these concerns, some sponsors create internal review boards to assess compassionate use requests independently from clinical operations.

Data Reporting and Post-Treatment Obligations

Compassionate use programs require robust documentation and follow-up. Common post-treatment regulatory requirements include:

• Submission of safety reports, including SAEs and SUSARs
• Ongoing benefit-risk assessments and potential adjustments to access criteria
• Annual summaries of patient outcomes for regulatory review
• Final report outlining the scope and results of the access program

EMA expects these reports as part of the pharmacovigilance package during marketing authorization review. FDA may incorporate the findings into approval considerations if collected under proper protocol.

Case Study: Compassionate Use in Spinal Muscular Atrophy (SMA)

In 2017, prior to full approval of a gene therapy for SMA, a compassionate use program was initiated for children with advanced disease stages. The program was administered under an FDA expanded access protocol and EMA’s Named Patient Program. Key features included:

• Centralized eligibility screening to ensure fair allocation
• Strict follow-up requirements for adverse events
• Real-time safety data submission to regulators
• Post-treatment monitoring up to 24 months

The data helped strengthen the marketing application and reassured regulators about the product’s safety and usability outside controlled settings.

Global Challenges and Future Outlook

Despite the value of compassionate use, global implementation faces several challenges:

• Lack of harmonized regulations across countries
• High administrative burden on physicians and sponsors
• Limited awareness among patient communities
• Ethical dilemmas in prioritizing patients for access

Future regulatory reform may focus on creating global access frameworks, simplifying application procedures, and enabling responsible use of real-world data generated from compassionate use.

Conclusion: Balancing Access, Ethics, and Safety

Compassionate Use Programs offer a critical bridge between investigational development and real-world patient need. Especially in rare diseases, where patients face dire prognoses, these programs reflect a balance of innovation, access, and ethical responsibility.

To navigate compassionate use from a regulatory perspective, sponsors and physicians must understand regional frameworks, adhere to ethical standards, and maintain transparent documentation. In doing so, they contribute not just to individual patient care but also to regulatory trust and long-term therapy development.